Successful treatment of refractory proliferative retinopathy of incontinentia pigmenti by intravitreal ranibizumab as adjunct therapy in a 4-year-old child

Conclusion: Intravitreal ranibizumab can be considered as an adjunct therapy in proliferative retinopathy secondary to incontinentia pigmenti when monotherapy with panretinal photocoagulation fails. Intravitreal ranibizumab may quickly inhibit the intraocular vascular endothelial growth factor and may prevent devastating complications like tractional retinal detachment. Extra caution has to be taken in adopting different dosages and injection regimes especially in pediatric cases.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research